Earlier in 2022, Accenture experts pored over the details of more than 300 mergers and acquisitions made by the 30 top biopharma companies between 2010 and 2021. They characterized the nature of those deals and found that 34% of all M&A focused on bolt-on, late-stage asset acquisitions.
But these, the experts observed, are “trending towards unsustainable,” as average takeout premiums for M&A deals valued at over $500m...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?